Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Silexion Therapeutics Corp (SLXN)

Silexion reports positive preclinical SIL204 data on lipoprotein-mediated cell uptake

Neutral Impact 3 of 5 other Written later

Silexion Therapeutics announced on September 28, 2026 preclinical findings that its lead candidate SIL204 uses naturally occurring serum lipoproteins to enter cancer cells and silence mutant KRAS. The study was in vitro, and the company said further pharmacokinetic and biodistribution studies are underway, so the results do not yet show clinical effect. The data supports the company's plan for systemic administration in its Phase 2/3 pancreatic cancer program.

Key points

  • In the study, depleting serum lipids cut SIL204 gene-knockdown efficiency by a statistically significant amount (P < 0.001).
  • Adding exogenous human LDL did not change gene-silencing potency compared with complete serum.
  • The company's Phase 2/3 trial targets locally advanced pancreatic cancer, with site initiation and regulatory clearances in Israel and Germany still in progress.
  • The filing contains no financial results, guidance or new capital figures.

The filing

CompanySilexion Therapeutics Corp (SLXN)
Form8-K, current report
Filed with the SECSep 28, 2026, 8:46 AM ET
Accession number0001178913-26-004628

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.